Eli Lilly said that its Q2 2023 results will include acquired IPR&D charges of approximately $97M, a charge of $0.09 on earnings per share.
https://seekingalpha.com/news/3987245-eli-lilly-sees-iprd-charges-negatively-impacting-q2-eps
Eli Lilly said that its Q2 2023 results will include acquired IPR&D charges of approximately $97M, a charge of $0.09 on earnings per share.
https://seekingalpha.com/news/3987245-eli-lilly-sees-iprd-charges-negatively-impacting-q2-eps
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.